These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 25590805)

  • 21. Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
    Proia DA; Zhang C; Sequeira M; Jimenez JP; He S; Spector N; Shapiro GI; Tolaney S; Nagai M; Acquaviva J; Smith DL; Sang J; Bates RC; El-Hariry I
    Clin Cancer Res; 2014 Jan; 20(2):413-24. PubMed ID: 24173541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.
    Liu H; Xiao F; Serebriiskii IG; O'Brien SW; Maglaty MA; Astsaturov I; Litwin S; Martin LP; Proia DA; Golemis EA; Connolly DC
    Clin Cancer Res; 2013 Sep; 19(18):5053-67. PubMed ID: 23900136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heat shock protein 90 as a molecular target for therapy in oral squamous cell carcinoma: Inhibitory effects of 17‑DMAG and ganetespib on tumor cells.
    Shiraishi N; Onda T; Hayashi K; Onidani K; Watanabe K; Sekikawa S; Shibahara T
    Oncol Rep; 2021 Feb; 45(2):448-458. PubMed ID: 33416122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.
    Jansson KH; Tucker JB; Stahl LE; Simmons JK; Fuller C; Beshiri ML; Agarwal S; Fang L; Hynes PG; Alilin AN; Lake R; Abbey YC; Cawley J; Tice CM; Yin J; McKnight C; Klummp-Thomas C; Zhang X; Guha R; Hoover S; Simpson RM; Nguyen HM; Corey E; Thomas CJ; Proia DA; Kelly K
    Sci Rep; 2018 Nov; 8(1):17239. PubMed ID: 30467317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HSP90 inhibition downregulates DNA replication and repair genes via E2F1 repression.
    Liu H; Lu Z; Shi X; Liu L; Zhang P; Golemis EA; Tu Z
    J Biol Chem; 2021 Aug; 297(2):100996. PubMed ID: 34302809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3.
    Nagaraju GP; Park W; Wen J; Mahaseth H; Landry J; Farris AB; Willingham F; Sullivan PS; Proia DA; El-Hariry I; Taliaferro-Smith L; Diaz R; El-Rayes BF
    Angiogenesis; 2013 Oct; 16(4):903-17. PubMed ID: 23838996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy.
    Nagaraju GP; Alese OB; Landry J; Diaz R; El-Rayes BF
    Oncotarget; 2014 Oct; 5(20):9980-91. PubMed ID: 25296971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response.
    Zhao Z; Zhu J; Quan H; Wang G; Li B; Zhu W; Xie C; Lou L
    Oncotarget; 2016 May; 7(20):29648-63. PubMed ID: 27105490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer.
    Nagaraju GP; Wu C; Merchant N; Chen Z; Lesinski GB; El-Rayes BF
    Cancer Lett; 2017 Aug; 402():110-116. PubMed ID: 28583846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
    Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL
    J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib.
    Landmann H; Proia DA; He S; Ogawa LS; Kramer F; Beißbarth T; Grade M; Gaedcke J; Ghadimi M; Moll U; Dobbelstein M
    Cell Death Dis; 2014 Sep; 5(9):e1411. PubMed ID: 25210794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.
    Weber H; Valbuena JR; Barbhuiya MA; Stein S; Kunkel H; García P; Bizama C; Riquelme I; Espinoza JA; Kurtz SE; Tyner JW; Calderon JF; Corvalán AH; Grez M; Pandey A; Leal-Rojas P; Roa JC
    Oncotarget; 2017 Apr; 8(16):26169-26184. PubMed ID: 28412732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FM807, a curcumin analogue, shows potent antitumor effects in nasopharyngeal carcinoma cells by heat shock protein 90 inhibition.
    Ye M; Huang W; Wu WW; Liu Y; Ye SN; Xu JH
    Oncotarget; 2017 Feb; 8(9):15364-15376. PubMed ID: 28157708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.
    Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA
    Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ganetespib radiosensitization for liver cancer therapy.
    Chettiar ST; Malek R; Annadanam A; Nugent KM; Kato Y; Wang H; Cades JA; Taparra K; Belcaid Z; Ballew M; Manmiller S; Proia D; Lim M; Anders RA; Herman JM; Tran PT
    Cancer Biol Ther; 2016 Apr; 17(4):457-66. PubMed ID: 26980196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice.
    Youssef ME; Cavalu S; Hasan AM; Yahya G; Abd-Eldayem MA; Saber S
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.
    Proia DA; Sang J; He S; Smith DL; Sequeira M; Zhang C; Liu Y; Ye S; Zhou D; Blackman RK; Foley KP; Koya K; Wada Y
    Invest New Drugs; 2012 Dec; 30(6):2201-9. PubMed ID: 22227828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resveratrol synergizes with cisplatin in antineoplastic effects against AGS gastric cancer cells by inducing endoplasmic reticulum stress‑mediated apoptosis and G2/M phase arrest.
    Ren M; Zhou X; Gu M; Jiao W; Yu M; Wang Y; Liu S; Yang J; Ji F
    Oncol Rep; 2020 Oct; 44(4):1605-1615. PubMed ID: 32945472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma.
    Giubellino A; Sourbier C; Lee MJ; Scroggins B; Bullova P; Landau M; Ying W; Neckers L; Trepel JB; Pacak K
    PLoS One; 2013; 8(2):e56083. PubMed ID: 23457505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.